Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis
Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis
复制标题
DOI：
10.1093/jnci/92.16.1329
复制
发表时间：
2000-08-16
期刊：
影响因子：
--
通讯作者：
Bundred, NJ
中科院分区：
文献类型：
--
作者：
Byrne, GJ;Ghellal, A;Bundred, NJ
背景：血管生成是肿瘤生长和转移的先决条件。血管生成的替代标记物将有助于研究抗血管生成药物的有效性。我们研究了三种血清糖蛋白-血管细胞粘附分子-1（VCAM-1）、内皮选择素（E-选择素）和血管性血友病因子（VWF）-作为血管生成标志物的潜力。研究方法：采用酶联免疫吸附法测定93例早期乳腺癌患者术前血清VCAM-1、E-选择素和VWF水平，并与每个肿瘤的微血管密度、组织学特征和术后复发进行比较。将血清VCAM-1、E-选择素和VWF水平的变化与激素治疗开始后6个月或疾病进展时评估的疾病对激素治疗的反应进行比较。所有P值均为双侧。结果如下：在早期乳腺癌患者中，血清VCAM-1水平而E-选择素和VWF的表达与肿瘤微血管密度密切相关（r = .65; P <0.001），早期复发的妇女术前血清VCAM-1水平高于未复发的妇女（P = 0.01），晚期乳腺癌患者的血清VCAM-1水平升高（P <0.001）但在病情稳定或对激素治疗有部分反应的晚期乳腺癌患者中保持不变或下降。结论：血清VCAM-1可能是乳腺癌血管生成的替代标志物。因此，它的测量可能有助于评估目前处于II期试验的抗血管生成药物。
Background: Angiogenesis, the development of new blood vessels from pre-existing vasculature, is a prerequisite for tumor growth and metastasis. Surrogate markers for angiogenesis would be useful for studying the effectiveness of antiangiogenesis drugs. We examined the potential of three serum glycoproteins-vascular cell adhesion molecule-1 (VCAM-1), endothelial selectin (E-selectin), and von Willebrand factor (VWF)-to serve as markers for angiogenesis. Methods: Preoperative serum levels of VCAM-1, E-selectin, and VWF were measured by enzyme-linked immunosorbent assay in 93 women with early breast cancer and were compared with microvessel density in each tumor, histologic features, and recurrence after surgery, Serum samples were taken from 55 women with advanced breast cancer who were commencing hormonal therapy, both immediately before therapy and 3 months later. Changes in serum levels of VCAM-1, E-selectin, and VWF were compared with the response of the disease to hormonal therapy assessed 6 months after the start of hormone therapy or at disease progression. All P values are two-sided. Results: In women with early breast cancer, serum levels of VCAM-1 (but not of E-selectin or VWF) correlated closely with microvessel density in tumors (r = .65; P < .001), and women who developed early recurrence had higher preoperative levels of serum VCAM-1 than those who remained disease free (P = .01), Serum VCAM-1 levels rose in women with advanced breast cancer whose disease progressed (P < .001) but remained unchanged or fell in women with advanced breast cancer whose disease remained stable or showed a partial response to hormonal therapy. Conclusion: Serum VCAM-1 appears to be a surrogate marker of angiogenesis in breast cancer. Its measurement may, therefore, help in the assessment of antiangiogenesis drugs currently in phase II trials.